On Feb. 17, 2021, BioNTech announced results from an in vitro study that provided additional data on the capability of sera from individuals immunized with the Pfizer-BioNTech COVID-19 vaccine (BNT162b2) to neutralize SARS-CoV-2 with the South African variant spike protein.

This study, which builds on previous work, was conducted by Pfizer and the University of Texas Medical Branch, and results were published in the New England Journal of Medicine.